OncoMatch/Clinical Trials/NCT04378647
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Is NCT04378647 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Induction with Brentuximab vedotin (BV) and Induction without Brentuximab Vedotin for hodgkin lymphoma, adult.
Treatment: Induction with Brentuximab vedotin (BV) · Induction without Brentuximab Vedotin · Consolidation with Brentuximab Vedotin — A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Biomarker criteria
Required: CD30 positive (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: brentuximab vedotin (brentuximab vedotin)
Prior treatment with brentuximab vedotin
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify